XML 19 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Mergers and Acquisitions - Additional Information (Details) (USD $)
3 Months Ended 1 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Feb. 28, 2015
Aug. 08, 2014
Dec. 31, 2014
Mar. 06, 2014
Sep. 30, 2012
Business Acquisition [Line Items]              
Revenues $ 33,849,000us-gaap_Revenues $ 7,854,000us-gaap_Revenues          
Net loss attributable to Intrexon (27,097,000)us-gaap_NetIncomeLoss (4,115,000)us-gaap_NetIncomeLoss          
ActoGeniX NV              
Business Acquisition [Line Items]              
Percentage of outstanding common stock acquired     100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
       
Business acquisition, consideration paid, shares issued     965,377us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
       
Cash     32,739,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
       
Fair value of total consideration transferred     72,474,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
       
Business combination, acquisition related cost 446,000us-gaap_BusinessCombinationAcquisitionRelatedCosts
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
           
ActoGeniX NV | Selling, general and administrative              
Business Acquisition [Line Items]              
Business combination, acquisition related cost 409,000us-gaap_BusinessCombinationAcquisitionRelatedCosts
/ us-gaap_BusinessAcquisitionAxis
= xon_ActoGeniXNVMember
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember
           
Trans Ova Genetics, LC              
Business Acquisition [Line Items]              
Percentage of outstanding common stock acquired       100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Business acquisition, consideration paid, shares issued       1,444,388us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Cash       63,625,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Fair value of total consideration transferred       116,542,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Business combination, acquisition related cost         713,000us-gaap_BusinessCombinationAcquisitionRelatedCosts
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
   
Deferred cash consideration       20,115,000us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Revenues 18,926,000us-gaap_Revenues
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
           
Net loss attributable to Intrexon 237,000us-gaap_NetIncomeLoss
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
           
Business combination, consideration transferred and noncontrolling interest       127,875,000xon_BusinessCombinationConsiderationTransferredandNoncontrollingInterest
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
     
Possible future contingent payments to former equity holders             6,000,000xon_BusinessCombinationContingentConsiderationFuturePaymentsToEquityHoldersMaximum
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
Possible future contingent payments to former equity holders, current valuation 0us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
/ us-gaap_BusinessAcquisitionAxis
= xon_TransOvaGeneticsLcMember
           
Exemplar Genetics, LLC              
Business Acquisition [Line Items]              
Cash paid to acquire noncontrolling interest     1,566,000xon_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseofInterestbyParentCashPortion
/ us-gaap_BusinessAcquisitionAxis
= xon_ExemplarGeneticsLLCMember
       
Shares issued to acquire noncontrolling interest     307,074xon_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseofInterestbyParentSharesIssuedbyParent
/ us-gaap_BusinessAcquisitionAxis
= xon_ExemplarGeneticsLLCMember
       
Medistem, Inc.              
Business Acquisition [Line Items]              
Percentage of outstanding common stock acquired           100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Business acquisition, consideration paid, shares issued           714,144us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Cash           4,920,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Fair value of total consideration transferred           24,995,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Business combination, acquisition related cost         680,000us-gaap_BusinessCombinationAcquisitionRelatedCosts
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
   
Number of promissory notes settled upon the closing of the merger           2xon_NumberOfPromissoryNotesSettled
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Shares of merger consideration surrendered by acquiree management to reimburse for required payroll tax withholdings           17,695xon_SharesSurrenderedToPayWithholdingTaxesShares
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
 
Medistem, Inc. | Settlement of Promissory Notes              
Business Acquisition [Line Items]              
Fair value of total consideration transferred           707,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
/ us-gaap_NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis
= xon_PromissoryNotesMember
 
Medistem, Inc. | Selling, general and administrative              
Business Acquisition [Line Items]              
Business combination, acquisition related cost   $ 291,000us-gaap_BusinessCombinationAcquisitionRelatedCosts
/ us-gaap_BusinessAcquisitionAxis
= xon_MedistemIncMember
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingGeneralAndAdministrativeExpensesMember
         
Minimum              
Business Acquisition [Line Items]              
Weighted Average Useful Life (Years) 2 years            
Minimum | Trans Ova Genetics, LC              
Business Acquisition [Line Items]              
Weighted Average Useful Life (Years)       3 years      
Maximum              
Business Acquisition [Line Items]              
Weighted Average Useful Life (Years) 14 years            
Maximum | Trans Ova Genetics, LC              
Business Acquisition [Line Items]              
Weighted Average Useful Life (Years)       9 years